Novartis buys a new gene therapy for vision loss, and this is one preclinical venture that didn't come cheap
Cyrus Mozayeni got excited when he began to explore the academic work of Ehud Isacoff and John G. Flannery at UC Berkeley.
Together, they were engaged in finding a gene therapy approach to pan-genotypic vision restoration in patients with photoreceptor-based blindness, potentially restoring the vision of a broad group of patients. And they did it by using a vector to deliver the genetic sequence for light sensing proteins.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.